Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolvaptan in ADPKD (TEMPO 3:4)
NCT00428948Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Jan 2007
- Primary completion
- Jan 2012
- Modality
- Small Molecules
- Countries
- 15
01
Overview
A Phase 3 trial of tolvaptan in autosomal dominant polycystic kidney disease (ADPKD), sponsored by Otsuka Pharmaceutical Development & Commercialization. Started Jan 2007; status: completed.
02
Drugs
tolvaptan
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT00428948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00428948.